Advertisement
BMO Capital Markets Corp. and Canaccord Adams Inc. are acting as jointbook-running managers for the proposed offering, with Merriman Curhan Ford &Co. (Amex: MEM) acting as a co-manager.
Advertisement
This press release shall not constitute an offer to sell or thesolicitation of an offer to buy, nor shall there be any sale of thesesecurities in any jurisdiction in which such offer, solicitation or sale wouldbe unlawful prior to the registration or qualification under the securitieslaws of any such jurisdiction.
Copies of the preliminary prospectus supplement and accompanyingprospectus may be obtained from: BMO Capital Markets Corp., Attn: ProspectusDelivery Department, 3 Times Square, New York, New York 10036; Telephone:(212) 702-1969.
Bionovo, Inc.
Bionovo is a pharmaceutical company focused on the discovery anddevelopment of safe and effective treatments for women's health and cancer,markets with significant unmet needs and billions in potential annual revenue.The company applies its expertise in the biology of menopause and cancer todesign new drugs derived from botanical sources which have novel mechanisms ofaction. Based on the results of early and mid-stage clinical trials, Bionovobelieves they have discovered new classes of drug candidates within their richpipeline with the potential to be leaders in their markets. Bionovo isheadquartered in Emeryville, California and is traded on the Nasdaq CapitalMarket under the symbol, "BNVI". For more information about Bionovo and itsprograms, visit http://www.bionovo.com.
Forward Looking Statements
This release contains certain forward-looking statements relating to thebusiness of Bionovo, Inc. that can be identified by the use of forward-lookingterminology such as "believes," "expects," or similar expressions. Suchforward-looking statements involve known and unknown risks and uncertainties,including uncertainties relating to product development, efficacy and safety,regulatory actions or delays, the ability to obtain or maintain patent orother proprietary intellectual property protection, market acceptance,physician acceptance, third party reimbursement, future capital requirements,competition in general and other factors that may cause actual results to bematerially different from those described herein as anticipated, believed,estimated or expected. Certain of these risks and uncertainties are or will bedescribed in greater detail in our filings with the Securities and ExchangeCommission, which are available at http://www.sec.gov. Bionovo, Inc. is underno obligation (and expressly disclaims any such obligation) to update or alterits forward-looking statements whether as a result of new information, futureevents or otherwise.Company Contacts: Bionovo, Inc. Tom Chesterman, SVP & CFO Tel: 510.420.4189 [email protected] Media Katherina Audley Tel: 415.847.7295 [email protected]
SOURCE Bionovo, Inc.
